TY - JOUR
T1 - Healing refractory venous ulcers
T2 - New treatments offer hope
AU - Kirsner, Robert S.
AU - Baquerizo Nole, Katherine L.
AU - Fox, Joshua D.
AU - Liu, Sophia N.
N1 - Publisher Copyright:
© 2015 The Society for Investigative Dermatology.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Non-healing wounds are associated with an inflammatory and proteolytic wound environment, and recent therapeutic strategies have been focused on reversing these changes. Connexins, as members of gap junctions, are important in intercellular signaling and wound repair. Connexin 43 (Cx43) downregulation is associated with normal wound healing, and it has been found to be upregulated in non-healing venous leg ulcers (VLUs). Ghatnekar et al. (2014) report findings of a small phase II trial performed in Indian patients with chronic VLUs, reporting that ACT1, a mimetic peptide of Cx43, accelerates healing in the treatment group. Despite standard care with compression therapy and adjuvant therapy for refractory wounds, at present in clinical practice a significant number of patients remain unhealed. The potential for ACT1 exists to help heal refractory VLUs, but it faces additional regulatory hurdles.
AB - Non-healing wounds are associated with an inflammatory and proteolytic wound environment, and recent therapeutic strategies have been focused on reversing these changes. Connexins, as members of gap junctions, are important in intercellular signaling and wound repair. Connexin 43 (Cx43) downregulation is associated with normal wound healing, and it has been found to be upregulated in non-healing venous leg ulcers (VLUs). Ghatnekar et al. (2014) report findings of a small phase II trial performed in Indian patients with chronic VLUs, reporting that ACT1, a mimetic peptide of Cx43, accelerates healing in the treatment group. Despite standard care with compression therapy and adjuvant therapy for refractory wounds, at present in clinical practice a significant number of patients remain unhealed. The potential for ACT1 exists to help heal refractory VLUs, but it faces additional regulatory hurdles.
UR - http://www.scopus.com/inward/record.url?scp=84925230148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925230148&partnerID=8YFLogxK
U2 - 10.1038/jid.2014.444
DO - 10.1038/jid.2014.444
M3 - Article
C2 - 25501380
AN - SCOPUS:84925230148
VL - 135
SP - 19
EP - 23
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
SN - 0022-202X
IS - 1
ER -